Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity

 Abstract

This commentary provides the authors’ perspective on the article “Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial,” which has recently been published in The Lancet Oncology.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
1167 - 1168
doi
10.4161/onci.20591
Type
Author's View
 Metrics
 Cite This Article
 Permissions
Creative Commons License Permissions
 Reprints
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity